Acadia Pharmaceuticals | ACAD - L'Utile Ante Imposte





L'Utile Ante Imposte Cambiamento Data
Acadia Pharmaceuticals USD 3.98M 22.34M 2026-03
ALKERMES USD -61.93M 122.3M 2026-03
Alnylam Pharmaceuticals USD 221.65M 60.52M 2026-03
Biogen USD 377.7M 433.7M 2026-03
BioMarin Pharmaceutical USD 141.2M 168.36M 2026-03
Bristol-Myers Squibb USD 1.47B 1.64B 2025-12
Cara Therapeutics USD -4.91M 3.17M 2025-03
Corcept Therapeutics USD 9.91M 5.33M 2025-12
Cytokinetics USD -206.03M 23M 2026-03
Eisai JPY -7.94B 29.94B 2026-03
Eli Lilly USD 8.27B 1.03B 2025-12
Incyte USD 343.6M 46.34M 2026-03
J&J USD 7.82B 2.86B 2026-03
Moderna USD -799M 612M 2025-12
Neurocrine Biosciences USD 246.8M 7.4M 2026-03
Pfizer USD 5.18B 6.82B 2026-03
Prothena USD -21.58M 15.33M 2025-12
PTC Therapeutics USD -2.46M 136.62M 2026-03
Sarepta Therapeutics USD 343.17M 750.85M 2026-03
Ultragenyx Pharmaceutical USD -184M 56M 2026-03
Vanda Pharmaceuticals USD -22.92M 16.68M 2024-12
Vertex Pharmaceuticals USD 1.25B 78.1M 2026-03